Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT06361342 for Anxiety is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
Mayo ClinicSmartphones Aggravating Anxiety Symptoms 100
Clinical Trial NCT06361342 is an interventional study for Anxiety that is active, not recruiting. It started on March 8, 2024 with plans to enroll 100 participants. Led by Mayo Clinic, it is expected to complete by December 1, 2026. The latest data from ClinicalTrials.gov was last updated on January 14, 2026.
Brief Summary
The goal of this study is to assess if excessive use of smartphone apps of social media can impact a person's mental health. The study is aimed at improving the usage of smartphones which might help improve the mental health of patients. The goal is not to discourage the use of smartphones but instead to utilize smartphones in a way that they do not impact lives.
Official Title
Smartphones Aggravating Anxiety Symptoms: Experimental Study From Southeastern
Conditions
AnxietyOther Study IDs
- 23-003633
NCT ID Number
Start Date (Actual)
2024-03-08
Last Update Posted
2026-01-14
Completion Date (Estimated)
2026-12
Enrollment (Estimated)
100
Study Type
Interventional
PHASE
N/A
Status
Active, not recruiting
Keywords
Smartphones
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalGeneral decrease in smartphone use. Subjects will limit their time on smartphone. | General decrease in smartphone use Subjects will decrease their time on smartphone in general. |
ExperimentalAvoid certain social media apps Subjects will limit time on smartphone, in particular avoiding use of social media apps on the smartphone which includes Twitter, Facebook, Tik Tok, Instagram, and Pinterest. | Avoiding Social Media Apps Subjects will avoid use of social media apps on the smartphone which includes Twitter, Facebook, Tik Tok, Instagram, and Pinterest. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in anxiety | Measured using the General Anxiety Disorder 7-item (GAD 7) scale to assess severity of generalized anxiety disorder. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score for the seven items ranges from 0 to 21 where 0 is no anxiety, 1-4 is minimal anxiety, 5-9 is mild anxiety, 10-14 is moderate anxiety, and 15-21 is severe anxiety. | Day 1, 12 weeks |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in depression | Measured using the Patient Health Questionnaire 9-item (PHQ-9) scale used to assess severity of depression. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score for the seven items ranges from 0 to 27 where 0 is no depression, 1-4 is minimal depression, 5-9 is mild depression, 10-14 is moderate depression, and 15-19 is moderately severe depression and 20-27 severe depression. | Day 1, 12 weeks |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
- For patients aged 18 years or older experiencing mild symptoms of anxiety or depression and who have a GAD-7 score 5 and above.
- Patient should have smart phone and should be using Facebook, Instagram, Twitter, Tik Tok, and Pinterest social media apps.
- Patients should have email access.
- Any patient who uses a smartphone for tracking glucose for diabetes management, heart rate, or any chronic illness which is being managed through a smartphone app.
- Any patient who uses more than one personal smartphone
- Any patient who is a suicide risk as per PHQ-9 score, current recreational drug usage, or alcohol abuse.
- Any patient who has suicidal ideation as per PHQ-9 assessment before or during the study period will be excluded, (all patients will be monitored for suicidal ideation by PHQ-9 scoring method at day 1, week 6, and week 12, but it is the responsibility of the patient to inform the study team if they have developed any suicidal ideation throughout the study period).
- Patients with activated POA (Power of Attorney - Healthcare), diagnosis of mental retardation or current disability due to any psychiatric disorder or severe depression with a high risk of suicide should be excluded.
- Any patient currently undergoing ECT (electroconvulsive therapy) for severe depression.
- Any patient taking prescribed SSRIs/SNRIs, with a change and not taking them continuously in last 30 days (not a new diagnosis of anxiety). If change they will be excluded.
Mayo Clinic861 active studies to exploreStudy Responsible Party
Gagandeep Singh, Principal Investigator, Principal Investigator, Mayo Clinic
No contact data.
1 Study Locations in 1 Countries
Minnesota
Mayo Clinic Minnesota, Rochester, Minnesota, 55905, United States